09:12 AM EDT, 09/05/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Friday it has received clearance from Health Canada to start a phase 1b trial that will evaluate PALI-2108 for the treatment of fibrostenotic Crohn's disease.

The open-label study will enroll six to 12 patients to evaluate safety, pharmacokinetics and pharmacodynamics of the drug, with dosing expected to begin in H2, the company said.

Palisade said topline data from the trial is expected in Q1 2026.